Clinical trials: Non-Cirrhotic
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Portal Hypertension
Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension
Background \& Aims: Non-cirrhotic portal hypertension (NCPH) represents a relatively infrequent group of conditions. This work aimed at determining causes of NCPH and evaluating the role of some clinical, laboratory, imaging and…
- Trial name
- NCT02635815
- Testing
- Upper gastrointestinal endoscopy
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Hypertension, Portal, Interventional Radiology
Percutaneous Portal Vein Recanalization for Refractory Portal Hypertension in Children With Non-Cirrhotic Extrahepatic Portal Vein Obstruction
This monocentric, prospective, observational study aims to evaluate the clinical efficacy, safety, and technical success of percutaneous portal vein recanalization (PVR) performed via interventional radiology.
- Conditions
- Hypertension, Portal, Interventional Radiology, Percutaneous Portal Vein Recanalization (PVR), Extrahepatic Portal Vein Obstruction (EHPVO)
- Trial name
- PRIMO-01 (NCT07873021)
- Testing
- Percutaneous Portal Vein Recanalization (PVR)
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Papa Giovanni XXIII Hospital
Portal Hypertension, Budd-Chiari Syndrome
Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India
There is a need to re-evaluate the patients classified as NCPH and determine whether the new histological classification proposed by the VALDIG applies to the Indian scenario.
- Conditions
- Portal Hypertension, Budd-Chiari Syndrome, Non-Cirrhotic Portal Hypertension, Porto-Sinusoidal Vascular Diseases
- Trial name
- PSVD-India (NCT06054451)
- Where
- India
- Volunteers
- 210 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis C Virus (HCV)
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
The objectives of this study are to assess the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir adult formulation in adolescents ages 12 to 17 years and a pediatric formulation of glecaprevir and pibrentasvir in…
- Trial name
- DORA (NCT03067129)
- Testing
- Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 129 people
- Sponsor
- AbbVie
Non Cirrhotic Portal Hypertension
Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)
Background: Variceal bleeding is a major cause of morbidity and mortality in patients with Non Cirrhotic Portal Hypertension (NCPH).
- Trial name
- NCT01000779
- Testing
- Propranolol, multi band ligator for esophageal varices
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Govind Ballabh Pant Hospital
Hepatocellular Carcinoma, Non-cirrhotic Liver
Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases
Background: Majority of liver transplantation (LT) recipients for hepatocellular carcinoma (HCC) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis.
- Trial name
- NCT06364839
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xiao Xu
Cystic Fibrosis Liver Disease, Portal Hypertension Due to Cystic Fibrosis (Disorder)
Pre-emptive Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Cystic Fibrosis Related Liver Disease
Portal hypertension (PHT) and its sequelae are the most clinically important manifestation in cystic fibrosis related liver disease (CFLD), with end-stage liver failure as a late and rare manifestation.
- Conditions
- Cystic Fibrosis Liver Disease, Portal Hypertension Due to Cystic Fibrosis (Disorder), Portal Hypertension, Noncirrhotic
- Trial name
- NCT05037643
- Testing
- TIPS
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)